PMID- 18315702
OWN - NLM
STAT- MEDLINE
DCOM- 20080418
LR  - 20151119
IS  - 1440-1797 (Electronic)
IS  - 1320-5358 (Linking)
VI  - 13
IP  - 3
DP  - 2008 Jun
TI  - Urinary kallikrein excretion is related to renal function change and inflammatory 
      status in chronic kidney disease patients receiving angiotensin II receptor 
      blocker treatment.
PG  - 198-203
LID - 10.1111/j.1440-1797.2008.00933.x [doi]
AB  - AIM: This study was to evaluate the correlation of urinary kallikrein to renal 
      function, proteinuria and urinary cytokines in chronic kidney disease patients in 
      a longitudinal follow up. METHOD: We measured urinary kallikrein and cytokines in 
      50 patients who were followed up for 12 months. RESULTS: Using regression model 
      we found that the kallikrein excretion (estimated by log kallikrein/creatinine) 
      was positively correlated to log estimated glomerular filtration rate in the 
      beginning and the end of follow up (P = 0.049 and 0.006, respectively). No 
      correlation existed between kallikrein excretion and proteinuria. The kallikrein 
      excretion decreased after 12 months of follow up, which was also associated with 
      the decrease of log estimated glomerular filtration rate. There was a significant 
      positive correlation between the log urinary kallikrein and monocyte 
      chemoattractant protein-1 (MCP-1) concentration (correlation coefficient = 0.277; 
      P = 0.049). Urinary kallikrein excretion was also positively correlated with 
      serum MCP-1 level (correlation coefficient = 0.431; P = 0.002). No correlation 
      existed between urinary kallikrein and transforming growth factor beta-1 or 
      tumour necrosis factor-alpha concentration. CONCLUSION: Urinary kallikrein 
      excretion is positively correlated to renal function, serum and urinary 
      inflammatory mediator MCP-1 in chronic kidney disease patients. These findings 
      indicate that urinary kallikrein excretion may reflect the change of renal 
      function and kidney inflammatory status.
FAU - Chiang, Wen-Chih
AU  - Chiang WC
AD  - Department of Internal Medicine, National Taiwan University Hospital, Taipei, 
      Taiwan.
FAU - Lin, Shuei-Liong
AU  - Lin SL
FAU - Chen, Yung-Ming
AU  - Chen YM
FAU - Wu, Kwan-Dun
AU  - Wu KD
FAU - Tsai, Tun-Jun
AU  - Tsai TJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Nephrology (Carlton)
JT  - Nephrology (Carlton, Vic.)
JID - 9615568
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cytokines)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Transforming Growth Factor beta1)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 3.4.21.- (Kallikreins)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Biomarkers/urine
MH  - Chemokine CCL2/urine
MH  - Cytokines/blood/*urine
MH  - Female
MH  - Follow-Up Studies
MH  - *Glomerular Filtration Rate
MH  - Humans
MH  - Inflammation Mediators/blood/*urine
MH  - Kallikreins/*urine
MH  - Losartan/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Nephritis/drug therapy/*etiology/metabolism/physiopathology
MH  - Proteinuria/drug therapy/etiology/metabolism/physiopathology
MH  - Regression Analysis
MH  - Renal Insufficiency, Chronic/complications/*drug 
      therapy/metabolism/physiopathology
MH  - Time Factors
MH  - Transforming Growth Factor beta1/urine
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/urine
EDAT- 2008/03/05 09:00
MHDA- 2008/04/19 09:00
CRDT- 2008/03/05 09:00
PHST- 2008/03/05 09:00 [pubmed]
PHST- 2008/04/19 09:00 [medline]
PHST- 2008/03/05 09:00 [entrez]
AID - NEP933 [pii]
AID - 10.1111/j.1440-1797.2008.00933.x [doi]
PST - ppublish
SO  - Nephrology (Carlton). 2008 Jun;13(3):198-203. doi: 
      10.1111/j.1440-1797.2008.00933.x.